LifeMD, Inc. $LFMD Stake Decreased by UBS Group AG

UBS Group AG lessened its holdings in shares of LifeMD, Inc. (NASDAQ:LFMD) by 21.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 674,008 shares of the company’s stock after selling 189,014 shares during the period. UBS Group AG owned 1.40% of LifeMD worth $2,298,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. State of Alaska Department of Revenue raised its holdings in LifeMD by 694.2% during the fourth quarter. State of Alaska Department of Revenue now owns 20,022 shares of the company’s stock worth $67,000 after purchasing an additional 17,501 shares in the last quarter. SG Americas Securities LLC raised its holdings in LifeMD by 13.8% during the fourth quarter. SG Americas Securities LLC now owns 25,298 shares of the company’s stock worth $86,000 after purchasing an additional 3,061 shares in the last quarter. Magnus Financial Group LLC bought a new stake in LifeMD during the fourth quarter worth approximately $41,000. Connective Capital Management LLC bought a new stake in LifeMD during the third quarter worth approximately $566,000. Finally, PharVision Advisers LLC bought a new stake in LifeMD during the third quarter worth approximately $292,000. Institutional investors own 35.52% of the company’s stock.

LifeMD Stock Performance

LifeMD stock opened at $4.57 on Thursday. The firm has a market cap of $221.01 million, a price-to-earnings ratio of 91.42 and a beta of 2.03. LifeMD, Inc. has a 1 year low of $2.56 and a 1 year high of $15.84. The firm’s 50 day moving average price is $4.16 and its two-hundred day moving average price is $3.78.

LifeMD (NASDAQ:LFMD) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.06). The business had revenue of $50.16 million during the quarter, compared to analyst estimates of $48.84 million. LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%. As a group, equities analysts predict that LifeMD, Inc. will post 0.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on LFMD. Cantor Fitzgerald reissued an “overweight” rating on shares of LifeMD in a report on Tuesday, March 10th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of LifeMD in a report on Tuesday. Wall Street Zen cut LifeMD from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. BTIG Research reissued a “buy” rating and set a $10.00 target price on shares of LifeMD in a report on Monday, May 4th. Finally, UBS Group reissued a “buy” rating on shares of LifeMD in a report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.14.

LifeMD Profile

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.